

AMENDMENTS TO THE CLAIMS:

Please amend claims 37 and add new claims 47-51.

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-31. **(Canceled)**

32. **(Previously presented)** A pharmaceutical composition comprising
a) anti-Vpr monoclonal antibodies; and
b) a pharmaceutically acceptable carrier.

33. **(Previously presented)** A method of treating an individual exposed to HIV by administering an effective amount of anti-Vpr antibodies.

34. **(Previously presented)** A method of treating an individual who has been infected with HIV comprising the step of administering to said individual a therapeutically effective amount of anti-Vpr antibodies.

35. **(Canceled)**

36. **(Previously presented)** The pharmaceutical composition of claim 32 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

37. **(Currently amended)** A pharmaceutical composition comprising:

a) anti-Vpr antibodies that inactivate Vpr activity to reduce the rate of HIV viral production; inhibit Vpr enhancement of HIV replication; and

b) a pharmaceutically acceptable carrier;

wherein the anti-Vpr antibodies are present in an amount effective to reduce the rate of viral production inhibit HIV replication in an HIV infected individual.

38. **(Previously presented)** The pharmaceutical composition of claim 37 wherein the anti-Vpr antibodies are monoclonal antibodies.

39. **(Canceled)**

40. **(Previously presented)** The pharmaceutical composition of claim 37 wherein the composition is a sterile composition and the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

41. **(Previously presented)** The method of claim 33 wherein the anti-Vpr antibodies are monoclonal antibodies.

42. **(Canceled)**

43. **(Previously presented)** The method of claim 33 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

44. **(Previously presented)** The method of claim 34 wherein the anti-Vpr antibodies are monoclonal antibodies.

45. **(Canceled)**

46. **(Previously presented)** The method of claim 34 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

47. (New) The pharmaceutical composition of claim 32 wherein the anti-Vpr antibodies are present in an amount effective to reduce the rate of viral production in an HIV infected individual.

48. (New) The method of claim 34 wherein the anti-Vpr antibodies inactivate Vpr activity to reduce the rate of HIV viral production.

49. (New) The method of claim 48 wherein the anti-Vpr antibodies are monoclonal antibodies.

50. (New) The method of claim 34 wherein the anti-Vpr antibodies inactivate Vpr activity to reduce the rate of HIV viral production.

51. (New) The method of claim 50 wherein the anti-Vpr antibodies are monoclonal antibodies.